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a b s t r a c t
Exposure to cyanide can occur in a variety of ways, including exposure to smoke from cigarettes or fires,
accidental exposure during industrial processes, and exposure from the use of cyanide as a poison or
chemical warfare agent. Confirmation of cyanide exposure is difficult because, in vivo, cyanide quickly
breaks down by a number of pathways, including the formation of both free and protein-bound thio-
cyanate. A simple method was developed to confirm cyanide exposure by extraction of protein-bound
thiocyanatemoieties fromcyanide-exposedplasmaproteins. Thiocyanatewas successfully extracted and
subsequently derivatizedwith pentafluorobenzyl bromide for GC–MS analysis. Thiocyanate levels as low
as 2.5ngmL−1 and cyanide exposure levels as low as 175gkg−1 were detected. Samples analyzed from
smokers and non-smokers using thismethod showed significantly different levels of protein-bound thio-
cyanate (p<0.01). These results demonstrate the potential of this method to positively confirm chronic
cyanide exposure through the analysis of protein-bound cyanide in human plasma.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Cyanide is a toxic chemical that is used in many industries,
including gold and silver mining, pesticide production and han-
dling, electroplating, and chemical manufacturing. Exposure to
cyanide is possible through anumber of routes, including the inges-
tion of certain foods (e.g., almonds or cassava root) [1,2], exposure
to smoke from cigarettes or fires [3,4], accidental exposure during
industrial processes, and from the use of cyanide as a poison or
chemical warfare agent [5]. Acute cyanide exposure causes inca-
pacitation of oxygen utilization, disruption of electron transport,
tissue hypoxia, and can result in death [6]. Chronic exposure to
cyanide can also lead to a battery of adverse health conditions [7].
Chronic cyanide exposure can increase the size of the thyroid gland
leading to thyroid malfunction, degenerate cerebral white matter,
and significantly increase the incidence of other neuronal disor-
ders, such as ataxic neuropathy [8]. These health conditions can
have major consequences and may persist for many years follow-
ing the actual occurrence of cyanide exposure. Although the effects
of chronic cyanide exposure are documented, there is little infor-
mation to indicate the level of cyanide exposure that can stimulate
harmful health effects in humans [9].
∗ Corresponding author. Tel.: +1 605 688 6698.
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Detection and quantification of cyanide or its metabolites from
biological fluids is important to confirm exposure and permit
adequate time for treatment; however, cyanide’s volatility and
reactivity make it a difficult analyte to reliably detect and quan-
tify [10–13]. Cyanide has a half-life of less than 1h in biological
fluids [14], making direct detection difficult and sometimes unreli-
able [15,16]. Therefore, reliable determination of cyanide exposure
normally involves thedetectionof amorestable cyanidebiomarker.
Themajormetabolite of cyanide, thiocyanate, is formedby reaction
of a sulfur donor (e.g., thiosulfate) with cyanide and the enzyme
rhodanese [16,17]. Thiocyanate is considered more stable than
cyanide in vivo, but it can be introduced by routes other than
cyanide metabolism [1,2], making it difficult to use as a marker
of cyanide exposure. Cyanide also forms a minor metabolite, 2-
amino-2-thiazoline-4-carboxylic acid, or ATCA, by reacting with
cystine [18]. Thismetabolite is relatively stable andhas goodpoten-
tial as a biomarker for cyanide exposure [11–18], but there is little
information on its relevance as a marker of cyanide exposure.
Cyanide can also react with disulfide bonds in proteins to form
protein-bound thiocyanate [19]. Because certainproteins have long
half-lives [20–22], the analysis of thiocyanate protein adducts has
the potential to be a long-term repository for information regard-
ing cyanide exposure. Fig. 1 illustrates the reaction of cyanide with
cysteine residues to form a stable thiocyanate (–SCN) moiety in a
protein [19] and theproposedextractionof the thiocyanate adducts
under basic conditions.
0003-2670/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
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Although there are a number of methods to detect free thio-
cyanate from various biological fluids [13,23,24], there has been
very little investigation into the isolation and detection of protein-
bound thiocyanate adducts. By isolating plasma proteins and
extracting protein-bound thiocyanate, confirmation of cyanide
exposure may be possible. The method presented provides a
simple analytical method to isolate and analyze protein-bound
thiocyanate adducts. This method was used to determine chronic
low-level cyanide exposure through the analysis of smoker and
non-smoker plasma samples.
2. Experimental
2.1. Materials
2.1.1. Reagents
Sodium carbonate (Na2CO3), sodium cyanide (NaCN), and
tetrabutylammonium sulfate (TBAS) were purchased from
Sigma–Aldrich (St. Louis, MO, USA). An isotopically labeled internal
standard, NaSC13N15, was obtained from Isotec (Miamisburg, OH,
USA). The derivatization agent, pentafluorobenzyl bromide, PFBBr,
was acquired from Thermo Scientific (Hanover Park, IL, USA). All
aqueous solutions were prepared with deionized, distilled water
(18M cm) from a Labconco Water Pro PS system. All organic
solvents used in these experiments were at least HPLC grade.
An aqueous stock solution of thiocyanate (100mM) was pre-
paredanddiluted to thedesired concentration for eachexperiment.
A stock solution of 10mMcyanidewas prepared by dissolving solid
NaCN in 10mM sodium hydroxide to prevent the formation of
gaseous hydrogen cyanide.
2.1.2. Biological fluids
Non-sterile, swine plasma with EDTA anti-coagulant was
obtained from Pelfreeze Biologicals (Rogers, AR, USA) and stored
at −80 ◦C until used. Human plasma samples were isolated from
smoking and non-smoking volunteers (six each). Blood samples
were collected from volunteers and mixed with an EDTA anti-
coagulant to prevent clotting. Plasma was isolated from the blood
samples by centrifugation and stored at −80 ◦C until analysis.
Collection and analysis of human samples was approved prior
to this study by the Human Subjects Advisory Committee at
South Dakota State University, the Avera Medical Institute (Sioux
Falls, SD), and the Human Research Protection Office of the U.S.
Army Medical Research and Materiel Command (Ft. Detrick, MD).
2.2. Methods
2.2.1. Formation and extraction of plasma protein adducts
To mimic cyanide exposure, swine plasma was incubated with
aqueous NaCN at room temperature for 3h to allow the forma-
tion of thiocyanate–protein adducts. Plasma proteinswere isolated
by precipitation using acidified acetone; the resulting precipitate
was washed with acidified acetone and diethyl ether three times
each. The precipitated proteins were dried and then dissolved in
an aqueous 0.1M carbonate buffer solution at a pH of 10 to initi-
ate hydrolysis of the thiocyanate adducts (Fig. 1). The solution was
shaken at room temperature for 1h to extract the protein-bound
thiocyanate.
2.2.2. Internal standard
After hydrolysis, isotopically labeled thiocyanate (30L of
100gmL−1 NaSC13N15) was added to the buffered protein solu-
tion to act as an internal standard. Because the internal standard
only differs from the analyte by two mass units, there is a slight
possibility of error due to mass carryover of thiocyanate isotopes
(the natural occurrence of the interfering isotope relative to the
predominant form is approximately 0.003%). Therefore, a signifi-
cantly larger amount of internal standard relative to the analyte
was used to minimize any interference.
2.2.3. Analysis of extracted thiocyanate
The extracted thiocyanatewas analyzed by GC–MS after deriva-
tization based on the method reported by Kage et al. [25]. Briefly,
200L of the extracted protein solution was mixed with 10mM
PFBBr in ethyl acetate and 20mM of TBAS in saturated sodium
borate. The samples were heated at 80 ◦C for 1h, shaken, and then
centrifuged to separate the organic and aqueous layers. The organic
layer was then collected and analyzed using electron ionization
GC–MS.
An Agilent GC–MS system equipped with a 6890N gas chro-
matograph and a 5975B inert XL electron ionization (EI)/chemical
ionization (CI) mass selective detector was used for the analysis of
derivatized thiocyanate. The columnconsisted of aDB-5MSbonded
phase column (30m×0.25mm I.D., 0.25m film thickness; J & W
Scientific, Santa Clara, CA) with helium carrier gas set at a flow
rate of 0.1mLmin−1. Initially, the temperature was set at 90 ◦C for
1min, and then increased 10 ◦Cmin−1 to 200 ◦C. The temperature
was thenquickly increased to270 ◦Cat60 ◦Cmin−1. Thederivatized
thiocyanate molecular ion and internal standard molecular ion of
Fig. 1. The reaction of cysteine residues with cyanide to form thiocyanate adducts on proteins and the subsequent removal of thiocyanate under basic conditions.
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239 m/z and 241 m/z, respectively, were monitored in selected ion
monitoring mode. Ions with 181 and 161 m/z were also monitored
for peak confirmation. A dwell time of 100ms was used for each of
the monitored ions.
3. Results and discussion
3.1. Extraction optimization
Thiocyanate adducts were successfully extracted from cyanide-
exposed swine plasma through base hydrolysis. The pH, duration
of the hydrolysis, and temperature of hydrolysis were optimized
for the extraction of thiocyanate and were found to maximize
extraction when performed at room temperature for 1h in aque-
ous solutions buffered at pH 10. To determine the optimal time for
thiocyanate hydrolysis, the duration of the hydrolysis was varied
from 2min to 12h (Fig. 2). Within the first 30min of hydrolysis,
the concentration of extracted thiocyanate increased rapidly and
then becomes essentially constant. The variability of the extrac-
tion was relatively large during the first 30min of hydrolysis, but
decreased significantly after 30min. The effect of pH on the hydrol-
ysis was also examined at various values ranging from 8 to 11. As
seen in Fig. 3, the largest amount of thiocyanate was extracted at a
Fig. 2. Thiocyanate extracted from plasma proteins as a function of time (2min to
6h). Error bars denote standard deviation.
Fig. 3. The concentration of thiocyanate released from plasma proteins as the pH of
hydrolysis was varied from 8 to 11. Error bars denote standard deviation.
Fig. 4. The amount of thiocyanate extracted from plasma proteins as a function
of the cyanide dose. The solid line was calculated with a Langmuir model for the
binding of cyanide by plasma proteins (Tsites = 4.8mol; K=7.0×10−4). Error bars
denote standard deviation.
pH value of 10 and the error for each pH value was low. Finally, the
temperature of the hydrolysis was examined at room temperature
(21 ◦C), 30 ◦C, and 50 ◦C. No significant difference in the amount
of extracted thiocyanate was found between these temperatures
(data not shown).
3.2. Detection limit and linearity
The detection limit was estimated to be 2.5ngmL−1 of thio-
cyanate in the extraction matrix, at a signal-to-noise ratio of 3:1.
This is comparable to the 1ngmL−1 detection limit of aqueous thio-
cyanate reported by Kage et al. [25]. The linearity of thiocyanate
analysis in the extracted protein matrix was tested from 1M to
100M and was found to be linear (R2 =0.996).
3.3. Dose–response study
Pigplasmawasexposed to aqueous cyanide solutions at concen-
trations ranging from 2M to 5mM. The resulting dose response
can be seen in Fig. 4. As the dose of cyanide increases, the
amount of bound cyanide, and subsequently the amount of thio-
cyanate extracted increases. As expected, thiocyanate levels did
not increase in a linear manner. After an intial quick rise in the
amount of extracted thiocyanate (i.e., protein-bound cyanide), the
amount of extracted thiocyanate did not increase at the same rate
relative to the cyanide dose. The nonlinear relationship between
the dose of cyanide and the extracted thiocyanate implies there is
maximumnumber of disulfide bonds in the protein that can be sat-
uratedwith the cyanide to form cyanide adducts. It should be noted
that the small amount of thiocyanate extracted from plasma sam-
ples that were not exposed to cyanide is due to naturally occuring
cyanide (i.e., exposure to cyanide through diet and environmental
exposure).
A Langmuirmodelwas employed to investigate the relationship
between the protein-bound cyanide relative to the concentration
of cyanide available in solution (Eq. (1))
[CN−]bound =
TsitesK[CN
−]dissolved
1 + K[CN−]dissolved
(1)
The [CN−]bound is the concentration of cyanide bound to the
plasma proteins and assumed to be equivalent to the thiocyanate
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Fig. 5. The chromatograms of extracted thiocyanate from the plasma proteins from
a non-smoker and a smoker, along with a 10M thiocyanate standard and a blank
(water).
extracted. [CN−]dissolved represents the aqueous cyanide concen-
tration in the presence of the plasma proteins. The value for
[CN−]dissolved was calculated by subtracting the cyanide bound to
the proteins from the concentration of cyanide that was initially
introduced to the plasma sample. Tsites represents the amount of
sites available to form thiocyanate adducts with cyanide and K
represents the equilibrium constant of cyanide binding.
Using Eq. (1), the values of K and Tsites were adjusted to best
describe the experimental data and [CN−]bound was then plotted
against the experimental values in Fig. 5. The values of K and
Tsites were found to be approximately 7.0×10−4 and 4.8mol,
respectively. If Tsites is assumed to be the number of disulfide sites
available, this is significantly less than the actual amount of disul-
fide moieties in plasma proteins, reported to be approximately
55.3mol per 1g of protein in swine plasma [26]. This suggests
that not all disulfide bonds react with cyanide. This may be due
to inaccessibility of disulfide bonds to cyanide due to their location
within the protein. Incomplete extraction of the bound thiocyanate
could also contribute to a lower calculated value of Tsites.
3.4. Analysis of human plasma
The proposed method’s applicability for cases of chronic expo-
surewas tested by analyzinghumanplasma samples obtained from
smokers and non-smokers. Twelve samples were obtained from
human volunteers in total; six samples from cigarette smokers and
six samples fromnon-smokers. The plasma proteinswere analyzed
for bound cyanide by the optimized extraction procedure. Repre-
sentative chromatograms of 10M standard thiocyanate solution
as well as extracted thiocyanate from plasma samples of a smoker
and a non-smoker are provided in Fig. 5. PFBBr derivatized thio-
cyanate elutes at 5.6min with good resolution.
A significant difference was observed in the mean concen-
tration of thiocyanate extracted from the plasma proteins of
smokers compared to that of the non-smokers. Although there
is some endogenous thiocyanate bound to human plasma pro-
teins, as indicated by the low levels of thiocyanate found in the
plasma of non-smokers, therewere considerably elevated amounts
of thiocyanate bound to plasma proteins of smokers. In non-
smokers, the average concentration of protein-bound thiocyanate
was found to be approximately 35.4ngmL−1 with a standard devi-
ation of 7.5ngmL−1. The amount of thiocyanate bound to the
plasma proteins of smokers was significantly elevated (p<0.01);
an average concentration of 89.1ngmL−1 with a standard devia-
tion of 38.2ngmL−1 was found. Therefore, the analytical method
was successful at determining cases of chronic, low-dose cyanide
exposure.
4. Conclusions
The method reported provides a technique to extract and ana-
lyze thiocyanate bound to plasmaproteins usingGC–MS. Currently,
there are already a number of successful methods to analyze free
thiocyanate from biofluids, however, the simplemethod presented
here specifically targets thiocyanate moieties that are bound to
disulfide bonds in proteins and it successfully established signif-
icantly elevated levels of thiocyanate adducts from proteins of
smokers relative to non-smokers.
Currently, a more expansive study of human plasma proteins
in smokers and non-smokers is underway to determine endoge-
nous concentrations of bound thiocyanate, as well as to establish
the variance between smokers relative to non-smokers. The con-
centrations found will be used to demonstrate the applicability of
this method in cases of cyanide exposure in humans. Addition-
ally, future work includes the study of the lifetime of thiocyanate
adducts formed with plasma proteins by examining the existence
of these adducts over time.
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